Empagliflozin treatment pre- and post- acute myocardial infarction reduces no-reflow, inflammatory cell infiltration and infarct size while preserving cardiac function.

Back

ESC Professional Premium Access

Empagliflozin treatment pre- and post- acute myocardial infarction reduces no-reflow, inflammatory cell infiltration and infarct size while preserving cardiac function.

Session: Basic research in acute coronary syndromes

Topic: No Reflow

Speaker: Doctor P. Nikolaou (Athens, GR)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Panagiota Efstathia Nikolaou

National & Kapodistrian University of Athens, Athens (Greece)

1 follower

5 more presentations in this session

Carvedilol suppresses coronary artery spasm in A-kinase anchoring protein 150 knockout mouse

Speaker: Doctor Y. Konno (Hirosaki, JP)

Nonalcoholic fatty liver disease worsens cardiac repair after myocardial infarction

Speaker: Doctor F. Hamidou (Paris, FR)

Mortality related to left ventricular ejection fraction and obstructive coronary artery disease in non-ST-segment elevation myocardial infarction

Speaker: Doctor N. Stoedkilde-Joergensen (Aarhus, DK)

TLR7 deficiency alleviated myocardial ischemia reperfusion injury via regulating macrophage-neutrophil interaction

Speaker: Doctor Y. Lai (Singapore, SG)

Soluble amyloid precursor protein-alpha mediates post-ischemic neovascularization after myocardial infarction

Speaker: Doctor H. Kawase (Bad Nauheim, DE)

Access the full session

Basic research in acute coronary syndromes

Speakers: Doctor P. Nikolaou, Doctor Y. Konno, Doctor F. Hamidou, Doctor N. Stoedkilde-Joergensen, Doctor Y. Lai...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources